<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847728</url>
  </required_header>
  <id_info>
    <org_study_id>CA209-234</org_study_id>
    <nct_id>NCT02847728</nct_id>
  </id_info>
  <brief_title>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</brief_title>
  <official_title>Pattern of Use and Safety/Effectiveness of Nivolumab in Routine Oncology Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, multicenter study in patients treated with nivolumab for the
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the
      United States (US). Targeted countries in the EU for study participation include Austria,
      Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). Study objectives are to
      assess the safety experience, survival, adverse event management, and outcomes of adverse
      events associated with nivolumab in routine oncology care facilities.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, multicenter study in patients treated with nivolumab for the
      approved indications of melanoma and lung cancer in Australia, the EU, Switzerland, and the
      United States (US). Targeted countries in the EU for study participation include Austria,
      Belgium, France, Germany, Italy, Spain, and the United Kingdom (UK). Study objectives are to
      assess the safety experience, survival, adverse event management, and outcomes of adverse
      events associated with nivolumab in routine oncology care facilities. The study will be
      started in 2016, and data collection will be continued until March 2024.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 31, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related pneumonitis - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related colitis- Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related hepatitis - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related endocrinopathies - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis) - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of other immune-related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of severe infusion reactions- Melanoma</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related pneumonitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related colitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related hepatitis - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related nephritis/renal dysfunction - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related endocrinopathies - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of other immune related adverse events (eg, uveitis, pancreatitis, demyelination, Guillain-Barre Syndrome, myasthenic syndrome, and encephalitis) - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of severe infusion reactions - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence rate of and severity of immune-related rash (including toxic epidermal necrolysis), - Lung Cancer</measure>
    <time_frame>up to nine years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to nine years</time_frame>
    <description>Other nivolumab treatment-related AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Management of Immune-related AEs:</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcomes of Immune-related AEs:</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival:</measure>
    <time_frame>Up to nine years</time_frame>
    <description>1-, 2-, 3-, 4-, and 5-year overall and median survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nivolumab treatment pattern</measure>
    <time_frame>Up to nine years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Melanoma</condition>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm Design</arm_group_label>
    <description>The study encompasses a single arm design with 400 adults treated with nivolumab for histologically or cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically or cytologically confirmed lung cancer.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consists of 400 adults treated with nivolumab for histologically or
        cytologically confirmed melanoma and 800 adults treated with nivolumab for histologically
        or cytologically confirmed lung cancer in accordance with the approved indications in
        Australia, the EU, Switzerland, and the US. Target EU countries for patient enrollment
        include Austria, Belgium, France, Germany, Italy, Spain, and the UK. Patients who begin
        treatment with nivolumab for the first time will be enrolled in accordance with the
        approved indications and whose treatment strategy was determined independently from
        consideration of study participation. Treatment will be determined at the treating
        physician's discretion and with the patient's consent.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18

          -  Histologically or cytologically confirmed diagnosis of melanoma (including uveal
             melanoma) or lung cancer

          -  Treatment with commercial nivolumab for the first time, alone or in combination with
             ipilimumab, for the approved indications of nivolumab within 14 days before informed
             consent for this study OR in the case where treatment has not yet been initiated,
             documentation that the treatment strategy is determined before an informed consent to
             study participation, and treatment is initiated within 28 days after informed consent

        Exclusion Criteria:

          -  Prior participation in a clinical trial within the past 4 weeks

          -  Previously treated with anti-PD-1, anti-PD-L1, or anti-PD-L2 antibodies

          -  Previously treated with anti-CTLA-4 for lung cancer

          -  Current or pending participation in a clinical trial

          -  Current or pending systemic treatment for cancer other than melanoma and lung cancer

          -  Inability to comply with the study protocol

        Other protocol defined inclusion and exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact sites directly. If there in no contact information,</last_name>
    <phone>Please email:</phone>
    <email>clinical.trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and site #</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Fortiche, Site: 1909</last_name>
      <phone>760-416-4736</phone>
      <email>Claudia.fortiche@tenethealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Corrales cruz, Site: 1912</last_name>
      <phone>904-427-1217</phone>
      <email>astrid.corralescruz@21co.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lake City Cancer Care, LLC</name>
      <address>
        <city>Lake City</city>
        <state>Florida</state>
        <zip>32024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lanette Strosser, Site: 1907</last_name>
      <phone>386-755-2330</phone>
      <phone_ext>6214</phone_ext>
      <email>slstrosser@ccofnf.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>LaGrange</city>
        <state>Georgia</state>
        <zip>30240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Tolzien, Site: 1901</last_name>
      <phone>847-268-8200</phone>
      <email>shallmeyer@oncmed.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRISTUS St. Frances Cabrini Hospital</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre Beebe, Site: 1910</last_name>
      <phone>318-466-6026</phone>
      <email>Deirdre.beebe@christushealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>NMMC-Hematology and Oncology Clinic</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Summerford, Site: 1906</last_name>
      <phone>662-377-4550</phone>
      <email>aqsummerford@nmhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Prenger, Site: 1908</last_name>
      <phone>573-884-4979</phone>
      <email>PrengerS@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System/Overlook Medical Center</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Peloquin, Site: 1911</last_name>
      <phone>973-971-6298</phone>
      <email>Barbara.peloquin@atlantichealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Center - Anderson</name>
      <address>
        <city>Easton</city>
        <state>Pennsylvania</state>
        <zip>18045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn D. Seith, Site: 1902</last_name>
      <phone>484-503-4153</phone>
      <email>carolyn.seith@sluhn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's/Candler SC Cancer Specialist</name>
      <address>
        <city>Hilton Head Island</city>
        <state>South Carolina</state>
        <zip>29926</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebbeca McCunn, Site: 1913</last_name>
      <phone>843-689-2895</phone>
      <phone_ext>115</phone_ext>
      <email>mccunnr@sjchs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>William Beaumont Army Medical Canter</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melinda Abamukong, 1915</last_name>
      <phone>915-742-3432</phone>
      <email>MAbamukong@genevausa.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Smith, Site: 1905</last_name>
      <phone>210-916-3332</phone>
      <email>Peggy.s.smith56.ctr@mail.mil</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lismore</city>
        <state>New South Wales</state>
        <zip>2480</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Byrne, Site: 1001</last_name>
      <phone>+612 6629 4559</phone>
      <email>sonia.byrne@ncahs.health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wagga Wagga</city>
        <state>New South Wales</state>
        <zip>2650</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mari Lashbrook, Site 1002</last_name>
      <phone>+61 2 69321000</phone>
      <email>mlashbrook@riverinacancercare.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqui McBurnie, Site: 1003</last_name>
      <phone>+61 2 6051 5319</phone>
      <email>jmcburnie@bordermedonc.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Skye Ridley, Site: 1005</last_name>
      <phone>+61 8 6465 9204</phone>
      <email>skye.ridley@sjog.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Donau</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Errhalt, Site: 1101</last_name>
      <phone>+43 2732 9004 - 4360</phone>
      <email>Peter.Errhalt@krems.lknoe.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>InnsBruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriele Fraidl, Site: 1103</last_name>
      <phone>+43-512-504-81509</phone>
      <email>gabriele.fraidl@tirol-kliniken.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Gallowitsch, Site: 1102</last_name>
      <phone>+43 (0)463 538 DW 31 303</phone>
      <email>Sandra.Gallowitsch@kabeg.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brasschaat</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Herman, 1202</last_name>
      <phone>+32 3 650 52 77</phone>
      <email>Datanurse.onco@klina.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fem De Plus, 1203</last_name>
      <phone>+32 56 63 33 59</phone>
      <email>Fem.deplus@azgroeninge.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Yague, 1201</last_name>
      <phone>+32 81702843</phone>
      <email>caroline.yague@cmsenamur.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69002</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Flavien Devun, Site 1307</last_name>
      <phone>+334 78 86 37 80 (36 37 80)</phone>
      <email>flavien.devun@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sihem Dahou, 1305</last_name>
      <phone>+33 3839 35005</phone>
      <email>s.dahou@oncog.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Lebouc, Site: 1301</last_name>
      <phone>+33 450 637 133</phone>
      <email>mlebouc@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magali Gipon, 1304</last_name>
      <phone>+33 04 779 17157</phone>
      <email>Magali.gipon@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurore Komperdra, 1303</last_name>
      <phone>+33 5 67 77 17 58</phone>
      <email>komperdra.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vandoeuvre-les-Nancy Cedex</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>München</city>
        <state>Bavaria</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lerchenfeld</city>
        <state>Hamburg</state>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Regina Waldeck, Site: 1424</last_name>
      <phone>+49 40 22 60 46-50</phone>
      <email>r.waldeck@oncoresearch-lerchenfeld.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Gravenhorst-Muenter</last_name>
      <phone>+49 40 22 60 46-52</phone>
      <email>u.muenter@oncoresearch-lerchenfeld.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Giessen</city>
        <state>Hesse</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Müller, Site: 1428</last_name>
      <phone>+49 641 985-42604</phone>
      <email>Sharon.Mueller@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Greifswald</city>
        <state>Mecklenburg-Western Pomerania</state>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigshafen</city>
        <state>Rhineland-Palatinate</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Augsburg</city>
        <zip>DE-86179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ballenstedt</city>
        <zip>06493</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bochum</city>
        <zip>5644791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bonn</city>
        <zip>53115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bettina Buergel, Site 1436</last_name>
      <phone>+0049 2241 595423</phone>
      <email>mailto:studienbuero@zaho-rheinland.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bremerhaven</city>
        <zip>27574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Buxtehude</city>
        <zip>DE-21614</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jena</city>
        <zip>DE-07743</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kassel</city>
        <zip>DE-34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julia Lutschkin, Site 1434</last_name>
      <phone>0049 261 921 5693-21</phone>
      <email>j.lutschkin@invo-koblenz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dorothee Neise, Site: 1415</last_name>
      <phone>+49(0)2151 780 250</phone>
      <email>Neise@Onkologie-Krefeld.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gudrun Klauke, Site: 1419</last_name>
      <phone>+49 (0)0221 8907 13962</phone>
      <email>klaukeg@kliniken-koeln.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>155131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baerbel Kaesberger, Site: 1426</last_name>
      <phone>+49 6131/147 224</phone>
      <email>b-kaesberger@kkmainz.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Minden</city>
        <zip>DE-32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Muenster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munchen</city>
        <zip>DE-80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Astrid Borgmeier, Site: 1409</last_name>
      <phone>+49 (0)89 4400 - 52590</phone>
      <email>Astrid.Borgmeier@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Quedlinburg</city>
        <zip>DE-06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anja von Schönfeld, Site: 1418</last_name>
      <phone>+49 (0)2361 9042724</phone>
      <email>vonschoenfeldi@oncologianova.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Regensburg</city>
        <zip>DE93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Loewigt, Site: 1421</last_name>
      <phone>0049 (0)381-760 1704</phone>
      <email>Loewigt.wk-nord@hotmail.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saarbruecken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Martini, 1435</last_name>
      <phone>+0049 (0)681-8576646</phone>
      <email>tanja.martini@onkosaar.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Traunstein</city>
        <zip>383278</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ursula Ghasemi, Site: 1404</last_name>
      <phone>0049 0861 7051 263</phone>
      <email>Ursula.Ghasemi@kliniken-sob.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ulm</city>
        <zip>23 89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Kirschbaum, Site: 1412</last_name>
      <phone>+49-731-500-45521</phone>
      <email>Rebecca.Kirschbaum@uniklinik-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sant'Andrea Delle Fratte</city>
        <state>Perugia</state>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Colabrese, Site: 1504</last_name>
      <phone>0039 075 5784099</phone>
      <email>d.colabrese@yahoo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lucca</city>
        <state>Tuscany</state>
        <zip>55100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Dalle Mura, Site: 1505</last_name>
      <phone>0039 0583 970161</phone>
      <email>sperimentazione.oncologia@usl2.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O Vito Fazzi -Polo Oncologico</name>
      <address>
        <city>Lecce</city>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Annamaria Mauro, Site 1506</last_name>
      <phone>+39 0832 661962</phone>
      <email>mauroannamaria@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ravenna</city>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mrs Michela Spreafico, Site: 1502</last_name>
      <phone>0039 0544 286223</phone>
      <email>michela.spreafico@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Hematology Oncology Group</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Maysonet, Site: 1904</last_name>
      <phone>787-786-8088</phone>
      <email>Robert.hunter@uccaribe.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capilla de la Torre, Site:1602</last_name>
      <phone>00349953220306</phone>
      <email>oncojaen@fibao.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Barba, Site: 1601</last_name>
      <phone>+34917878600</phone>
      <phone_ext>2884</phone_ext>
      <email>luis.barba@fundacionmdanderson.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Beatriz Rivas, Site: 1604</last_name>
      <phone>+34923281199</phone>
      <phone_ext>55749</phone_ext>
      <email>brivas@saludcastillayleon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Salcedo, 1607</last_name>
      <phone>+34 942202525</phone>
      <email>ensayos.onc@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amalia González, Site: 1603</last_name>
      <phone>0034 925 269200</phone>
      <phone_ext>48632</phone_ext>
      <email>agblazquez@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena de Francisco, Site: 1606</last_name>
      <phone>+41 81 256 71 65</phone>
      <email>oncoavilacec@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Walter, 1703</last_name>
      <phone>+41 56 486 2765</phone>
      <email>beatrice.walter@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Chikhi, Site: 1702</last_name>
      <phone>+41 91 751 82 30</phone>
      <email>rebecca.chikhi@oncologia-pedrazzini.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB252ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Price, 1803</last_name>
      <phone>+44 1224 554361</phone>
      <email>Nicolaprice@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Boal, Site: 1801</last_name>
      <phone>0044 0117 342 7764</phone>
      <email>Helen.boal@UHBristol.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cornwall</city>
        <zip>TR1 3LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emma Duley, Site: 1802</last_name>
      <phone>+44 (0)1872 258342</phone>
      <email>emmaduley@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>http://www.fda.gov/safety/recalls/</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 28, 2016</study_first_submitted>
  <study_first_submitted_qc>July 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

